Synta Pharmaceuticals, Inc. (SNTA) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
New CEO Whitaker is Positive for Synta Pharma (SNTA); Roth Affirms at 'Buy' Following Q2 Results
August 6, 2014 2:10 PM EDTRoth Capital reaffirms its Buy rating and $27 target on Synta Pharmaceuticals, Inc. (Nasdaq: SNTA) following Q2 results and announcement of a... More
Synta Pharma (SNTA) Taps Sanofi's (SNY) Anne Whitaker as CEO
August 6, 2014 7:10 AM EDTSynta Pharmaceuticals, Inc. (Nasdaq: SNTA) announced that Anne Whitaker will join the Company as President, Chief Executive Officer and a member of the Companys Board of Directors effective September 2, 2014. Ms. Whitaker has more than 20 years of experience in the pharmaceutical industry, principally at GlaxoSmithKline and Sanofi (NYSE: SNY) including,... More
